COVID-19 Response - Drug Discovery and NanoMedicine

We have assembled a research team in response to COVID-19 pandemic based on our decade-long research experiences on drug structure optimization and nanotechnology.

Goals on COVID-19 response 

1. Evaluate drug-like potentials of the reported compounds against SARS-CoV-2 to achieve efficacy/safety in animals and in humans

2. Chemically optimize drugs for tissue targeting against SARS-CoV-2 in targeted organs to improve efficacy/safety in animals and humans

3. Utilize nanotechnology to improve drug's tissue targeting against SARS-CoV-2 to improve efficacy/safety in animals and humans

Publications and Patents on COVID-19 response 

1. Duxin Sun. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Delivery May Offer Additional Benefit. The AAPS Journal, 22, 77,  2020 (Submitted on April 7, Accepted on April 13, published on May 26)

2. Duxin Sun, Wei Gao, Hongxiang Hu, Mohamed Dit Mady Traore, Yudong Song, and Bo Wen. Structurelly modified remdesivir analogs and nanoformulations for treating viral infections. US Provisional Patent Application 63/004 122, April 2, 2020 

Dr. Sun & Dr. Wen in lab

Principle Investigator

Dr. Duxin Sun is a Professor in the Department of Pharmaceutical Sciences and Charles R. Walgreen, Jr. Professor of Pharmacy in the College of Pharmacy at the University of Michigan. Dr. Sun serves as the Director of Pharmacokinetics (PK) Core. Dr. Sun also has a joint appointment in the Chemical Biology program, the Interdisciplinary Medicinal Chemistry program, and the University of Michigan’s Comprehensive Cancer Center.

Dr. Sun has published more than 220 papers, 120 meeting abstracts, 10 book chapters, and 12 U.S. patents. Dr. Sun has supervised 30 PhD students and 45 postdoctoral fellows and visiting scientists. Dr. Sun is a Fellow of American Association of Pharmaceutical Scientists (AAPS) and has served as chair of the PPB (Physical Pharmacy and Biopharmaceutics) section in AAPS. Dr. Sun serves on FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee. Dr. Sun is the President of the University of Michigan Association of Chinese Professors (UMACP) (2020-2022) and Vice President of American Chinese Pharmaceutical Association (ACPA) (2013-2019). Dr. Sun has served on study sections for NIH and FDA. 

Research - Drug Discovery and NanoMedicine 

1. Breast Cancer Stem Cells and Therapeutics

2. Drug Optimization Alters Tissue Targeting, Efficacy and Toxicity 

3. Nanotechnology for Drug Delivery

4. Virus Spike Mimicry NanoVaccine (VSM NanoVac) to activate B cell immunity

5. Intubation and Wireless Sampling Device in Human GI Track For Microbiome Analysis and Drug Product Optimization

 More information on the lab's research programs can be found here.

Lab Members

The Sun Lab research team is made up of about thirty individuals, including graduate students, postdoctoral research fellows, research scientists, and PK Core staff, as well as visiting research scientists. We have students from the Pharmaceutical Sciences department at the College of Pharmacy, from the Program in Chemical Biology, and from the Cellular and Molecular Biology department at LS&A. Our lab includes researchers with degrees in chemistry, biology, mathematics, and engineering. You can learn more about our lab members here, and check for open positions in the lab here

Lab Location

The Sun Lab is located at the North Campus Research Complex, Building 520, 1600 Huron Parkway, Ann Arbor, Michigan. Lab meetings are held weekly; the lab calendar is available here. For administrative concerns, please contact Erika Zucal, the lab's administrative assistant, at

Sun Lab group photo in lab

Listing Row

Tuesday, March 10, 2015
Tuesday, March 10, 2015